Do statins protect against upper gastrointestinal bleeding?

British Journal of Clinical Pharmacology

Volumn 67, Issue 4, 2009, Pages 460-465

  Gulmez, Sinem Ezgi ^a,b   Lassen, Annmarie Touborg ^c   Aalykke, Claus ^c   Dall, Michael ^c   Andries, Alin ^c   Andersen, Birthe Søgaard ^c   Hansen, Jane Møller ^c   Andersen, Morten ^b   Hallas, Jesper ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antithrombotic drugs; Case control study; Statins; Upper gastrointestinal bleeding

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; ATORVASTATIN; CERIVASTATIN; CLOPIDOGREL; DIPYRIDAMOLE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CELL PROTECTION; DENMARK; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MELENA; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; UPPER GASTROINTESTINAL BLEEDING;

AGED; AGED, 80 AND OVER; ASPIRIN; CASE-CONTROL STUDIES; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ODDS RATIO; TREATMENT OUTCOME;

EID: 63849095788     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03362.x     Document Type: Article

References (21)

1. Endo A. The discovery and development of HMG-coa reductase inhibitors. J Lipid Res 1992 33 : 1569 82.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report, National Cholesterol Education Program National Heart, Lung, and Blood Institute, National Institutes of Health (NIH) Publication No. 02-5215. September 2002.
3. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 1999 286 : 1946 49.
4. Friis S, Olsen JH. Statin use and caner risk: an epidemiologic review. Cancer Invest 2006 24 : 413 24.
5. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000 356 : 1627 31.
6. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999 30 : 1969 73.
7. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006 61 : 729 34.
8. Klein BEK, Klein R, Lee KE, Grady LM. Statin use and incident nuclear cataract. JAMA 2006 295 : 2752 8.
9. Teixeira GF, Kalil RAK, Prates PR, Sant'Anna JRM, Pellanda L, Homsi-Neto A, Nesralla IA, Alegre P. Pravastatin reduces the inflammatory response to cardiopulmonary bypass after coronary revascularization. Canadian Cardiovascular Congress 2003, 56th Annual Meeting of the CCS held jointly with the XIX InterAmerican Congress of Cardiology. October 24-29, 2003, Toronto, Ontario. Abstract no: 008.
10. Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis in Myocardial Infarction 16 (OPUS-TIMI 16) trial. Am Heart J 2006 151 : 976. e1 6.
11. Hallas J, Sørensen HT. Farmakoepidemiologi. Ugeskr Laeger 2005 167 : 2186 90.
12. Gaist D, Sørensen HT, Hallas J. The Danish prescription registers. Dan Med Bull 1997 44 : 445 8.
13. WHO Collaborating Centre for Drug Statistics Methodology 2006. ATC index with DDDs and Guidelines for ATC classification and DDD assignment. Oslo : Norwegian Institute of Public Health, http://www.whocc.no/atcddd (last accessed June 2008).
14. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, Andersen M, Lassen AT. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006 333 : 726 30.
15. Rothman KJ. Measuring disease occurrence and casual effects. In : Epidemiology: an Introduction. New York : Oxford University Press Inc., 2002 24 56.
16. Russell RI. Protective effects of the prostaglandins on the gastric mucosa. Am J Med 1986 81 : 2 4.
17. Chen JC, Huang KC, Wingerd B, Wu WT, Lin WW. HMG-CoA reductase inhibitors induce COX-2 gene expression in murine macrophages: role of MAPK cascades and promoter elements for CREB and C/EBPbeta. Exp Cell Res 2004 301 : 305 19.
18. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000 160 : 2093 9.
19. Weil J, Langman MJ, Wainwright P, Lawson DH, Rawlins M, Logan RF, Brown TP, Vessey MP, Murphy M, Colin-Jones DG. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000 46 : 27 31.
20. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk? Aliment Pharmacol Ther 2006 24 : 897 908.
21. Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Bøggild H, Olsen J, Sørensen HT. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005 60 : 534 42.